prikaz prve stranice dokumenta Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study
  Preuzmi
PDF 137.35 KB
Znanstveni rad - Izvorni znanstveni rad
Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study
Central European Journal of Immunology, 44 (2019), 1; 33-37. https://doi.org/10.5114/ceji.2019.84012
Marjanac, Igor; Lovrić, Robert; Barbić, Jerko

Citirajte ovaj rad

Marjanac, I., Lovrić, R. i Barbić, J. (2019). Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study. Central European Journal of Immunology, 44. (1), 33-37. doi: 10.5114/ceji.2019.84012

Marjanac, Igor, et al. "Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study." Central European Journal of Immunology, vol. 44, br. 1, 2019, str. 33-37. https://doi.org/10.5114/ceji.2019.84012

Marjanac, Igor, Robert Lovrić i Jerko Barbić. "Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study." Central European Journal of Immunology 44, br. 1 (2019): 33-37. https://doi.org/10.5114/ceji.2019.84012

Marjanac, I., Lovrić, R. i Barbić, J. (2019) 'Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study', Central European Journal of Immunology, 44(1), str. 33-37. doi: 10.5114/ceji.2019.84012

Marjanac I, Lovrić R, Barbić J. Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study. Central European Journal of Immunology [Internet]. 2019. [pristupljeno 19.04.2024.];44(1):33-37. doi: 10.5114/ceji.2019.84012

I. Marjanac, R. Lovrić i J. Barbić, "Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study", Central European Journal of Immunology, vol. 44, br. 1, str. 33-37, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:239:694084. [Citirano: 19.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:239:694084
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study
AutorIgor Marjanac
MBZ: 371805
AutorRobert Lovrić
MBZ: 343885
AutorJerko Barbić
MBZ: 258420
Autorova ustanova(Klinički bolnički centar Osijek)
Autorova ustanovaSveučilište Josipa Jurja Strossmayera u Osijeku
Fakultet za dentalnu medicinu i zdravstvo Osijek
Autorova ustanovaSveučilište Josipa Jurja Strossmayera u Osijeku
Medicinski fakultet Osijek
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička imunologija
Sažetak (engleski)
INTRODUCTION: The involvement of the high-mobility group box 1 protein (HMGB1) in various autoimmune and inflammatory diseases has been documented; however, the role of this proinflammatory molecule in children with diabetes type 1 (T1DM) has not been addressed. The aim of this case-control study is to compare the serum level of HMGB1 in children with newly diagnosed T1DM (group 1) and a control group composed of healthy children. MATERIAL AND METHODS: This case-control study included 136 children: group 1 (n = 96) and a control group (n = 40). Measurements were taken from serum for the following: HMGB1, white blood cell count, C-reactive protein, glucose, haemoglobin A1C, and β-cell autoantibodies (GADA-65, IA-2, ICA). HMGB1 was determined using enzyme-linked immunosorbent assay on a Labsystems iEMS Reader MF analyser (Labsystems Diagnostics Oy, Helsinki, Finland). RESULTS: The level (median and interquartile range) of HMGB1 was statistically higher (p < 0.001) in children with T1DM: 8.7 (5.0-9.8) µg/l, in comparison with the control group: 1.0 (0.6-1.4) µg/l. No correlation was found between HMGB1 and HbA1c in group 1, or between HMGB1 and BMI. A statistically higher percentage of positive children for autoantibodies were present in group 1 compared to the control group (p ≤ 0.001). HMGB1 serum levels were also tested and the presence of autoantibodies, and none of those antibodies correlated with the level of HMGB1. CONCLUSIONS: The higher level of HMGB1 in children with T1DM, compared to the control group, indicates that this proinflammatory molecule is a good candidate marker of inflammation in children with T1DM.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCentral European Journal of Immunology
Brojčani podacivol. 44, br. 1, str. 33-37
p-ISSN1426-3912
e-ISSN1644-4124
DOIhttps://doi.org/10.5114/ceji.2019.84012
URN:NBNurn:nbn:hr:239:694084
Datum objave publikacije2019
URL dokumentahttp://europepmc.org/abstract/MED/31114434
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Dijeli pod istim uvjetima 4.0 međunarodna (CC BY-NC-SA 4.0)
Datum i vrijeme pohrane2019-11-28 08:51:00